Accelerate Diagnostics - AXDX Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXDX, but not buy additional shares or sell existing shares.
View AXDX analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month target prices for Accelerate Diagnostics' stock. Their AXDX share price forecasts range from $1.00 to $1.00. On average, they predict the company's share price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 54.8%.
View analysts price targets for AXDX or view top-rated stocks among Wall Street analysts.

Accelerate Diagnostics' stock was trading at $5.22 at the beginning of the year. Since then, AXDX shares have decreased by 57.7% and is now trading at $2.21.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our AXDX earnings forecast.

Accelerate Diagnostics will be holding an earnings conference call on Monday, August 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "5773022".

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced its earnings results on Monday, May, 16th. The medical research company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.07. The medical research company had revenue of $2.96 million for the quarter, compared to analyst estimates of $2.90 million. During the same quarter in the previous year, the business posted ($0.41) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Griffin Asset Management Inc. (5.72%), JPMorgan Chase & Co. (0.54%), Belpointe Asset Management LLC (0.50%), Allworth Financial LP (0.22%), UBS Group AG (0.06%) and Baird Financial Group Inc. (0.04%). Insiders that own company stock include Hany Massarany, Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends.

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXDX stock can currently be purchased for approximately $2.21.

Accelerate Diagnostics (NASDAQ:AXDX) has a market capitalization of $153.95 million and generates $11.78 million in revenue each year. The medical research company earns $-77,700,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

The company employs 220 workers across the globe.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The official website for the company is acceleratediagnostics.com. The medical research company can be reached via phone at (520) 365-3100, via email at investors@axdx.com, or via fax at 520-269-6580.